- Home
- BCLI vs SILO Comparison
BCLI vs SILO Comparison
Compare BCLI & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- SILO
- Stock Information
- Founded
- BCLI 2000
- SILO 2010
- Country
- BCLI United States
- SILO United States
- Employees
- BCLI N/A
- SILO N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- SILO Apparel
- Sector
- BCLI Health Care
- SILO Consumer Discretionary
- Exchange
- BCLI Nasdaq
- SILO Nasdaq
- Market Cap
- BCLI 9.9M
- SILO 8.8M
- IPO Year
- BCLI N/A
- SILO N/A
- Fundamental
- Price
- BCLI $1.21
- SILO $1.08
- Analyst Decision
- BCLI Strong Buy
- SILO
- Analyst Count
- BCLI 1
- SILO 0
- Target Price
- BCLI $30.00
- SILO N/A
- AVG Volume (30 Days)
- BCLI 35.3K
- SILO 139.6K
- Earning Date
- BCLI 03-31-2025
- SILO 05-12-2025
- Dividend Yield
- BCLI N/A
- SILO N/A
- EPS Growth
- BCLI N/A
- SILO N/A
- EPS
- BCLI N/A
- SILO N/A
- Revenue
- BCLI N/A
- SILO $72,102.00
- Revenue This Year
- BCLI $170.09
- SILO $1.86
- Revenue Next Year
- BCLI N/A
- SILO N/A
- P/E Ratio
- BCLI N/A
- SILO N/A
- Revenue Growth
- BCLI N/A
- SILO N/A
- 52 Week Low
- BCLI $1.05
- SILO $0.77
- 52 Week High
- BCLI $11.25
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- BCLI 30.68
- SILO 28.08
- Support Level
- BCLI $1.12
- SILO $1.20
- Resistance Level
- BCLI $1.59
- SILO $1.39
- Average True Range (ATR)
- BCLI 0.11
- SILO 0.09
- MACD
- BCLI -0.02
- SILO -0.02
- Stochastic Oscillator
- BCLI 17.31
- SILO 0.00
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.